Our solution is to combine our proprietary urine test strip and new technology in our app for monitoring wellness and health. We offer users a convenient, accurate, cost-effective way to get an interpretation of 14 important health parameters in just two minutes, take a survey to collect a medical history taking, and, if necessary, consult a doctor.
MVP, +300 first active users
Mobile Health's global market is about $ 130 billion. Presently, we focus on the B-t-C segment. We focus on large markets with unmet needs: diabetes, women's health, keto diets. 1. Diabetes type 1 patients. 2. People with undiagnosed (asymptotic) diabetes. 3. Women's health: pre-eclampsia - 6% of all pregnancies affected 4. UTIs - 50% of women affected at least once in a lifetime. 5. Consumers who already actively use self-administered urine tests. Diabetes type 1 patients: 1.2 million in the US ($14 billion healthcare cost) 2. People with undiagnosed (asymptotic) diabetes - 10 million in the US 3. Women's health: pre-eclampsia - 6% of all pregnancies affected ($6 billion annual healthcare cost); UTIs - 50% of women affected at least once in a lifetime (1 million hospitalizations per year), $8 billion healthcare cost)
Problem or Opportunity
Many patients with chronic health conditions require timely urine tests that may help prevent serious disease complications, eliminate frequent doctor visits, and reduce related high healthcare costs. Existing self-administered urine tests (as evidenced by user feedback) are characterized by inconvenience, complexity in the meaningful interpretation of results, and lack of tracking dynamics.
Solution (product or service)
Our solution is to combine our proprietary urine test strip and new technology in our app for monitoring wellness and health. We offer an interpretation of 14 important health parameters in just two minutes, take a survey to collect a medical history, and consult a doctor. The urine test strip has 14 indicators: glucose, ketones, pH, blood, and other. By the color change we are talking about infections, kidney and liver disease, complications of diabetes, so - we say about metabolic disorders.
Competitors: Healthy.io - strengths: established market player, FDA cleared product weaknesses: expensive, lack of comprehensive analysis of different test parameters Scanwell - strengths: FDA cleared (UTIs only) weaknesses: expensive, limited scope, lack of comprehensive analysis of different test parameters Blo.om Vivoo
Advantages or differentiators
We have four important benefits for our users: First of all - The interpretation of several indicators, which makes this method better. Secondly - the 30 test strips in the set allow daily monitoring of the user's health. Third - using AI algorithms and doctors' experience based on diagnostic algorithms, we have the opportunity to combine the data of our analysis and history for better diagnosis. And finally - Using the collecting date, we connect the user with the doctor using TeleHealth protocols for quality and affordable medical care.
A recurring revenue model: free App comes with a monthly supply of our proprietary test strips for $8.99. After FDA Approve, we will be ready for the third step - finding a strategic partner for the provider Telehealth.
We target consumers who already actively use self-administered urine tests. We use internet marketing resources: Reddit, WebMD, HealthLine, social media, posting unique articles, etc. We plan to work with relevant experts: physicians, nutritionists, counselors, and other Influencers to promote our product. Today, we advertise on FB and Google. Customers are either directed to our website or directly to Google Play.
Money will be spent on
Development Budget – next 6 months Website. $12,000 Design $15,000 Android App $9,500 iOS App $15,500 Server, IT equipment $14,000 Branded Strips Inventory $16,000 Sales and Marketing $10,000 General and Administrative $8,000 TOTAL $100,000
Offer for investor
Pre-money valuation AssayMe - $1,000,000 Attracting $100,000 in exchange for 10% equity Creation of the Board of Directors and entry into its structure of an investor representative.